About CDC’s Work to Combat Antibiotic Resistance
With these investments, the Centers for Disease Control & Prevention (CDC), in partnership with health departments, academia, and healthcare, is transforming how the nation combats and slows antibiotic resistance at all levels, ensuring our ability to stand up a full, faster response to protect Americans from this threat.
These investments will better protect patients through:
-
Detection and Response
-
✔ Rapid detection and faster response to outbreaks and emerging resistance related to healthcare-associated infections, foodborne bacteria, and gonorrhea—to contain and control spread
-
✔ Gold-standard lab capacity offered to all state and regional labs through CDC’s Antibiotic Resistance Laboratory Network
-
Prevention of Infections
-
✔ Improve prevention of healthcare-associated infections, foodborne illness, and gonorrhea
-
✔ Empowered networks for prevention across healthcare and communities for threats like Clostridium difficile, methicillin-resistant Staphylococcus aureus (MRSA), and “nightmare bacteria” carbapenem-resistant Enterobacteriaceae (CRE)
-
✔ Insights for research innovation and better patient care
-
Improving Antibiotic Use
-
✔ Ensure antibiotics work to protect patients from life-threatening infections or sepsis
-
✔ Protect patients from unintended consequences associated with antibiotic use, including adverse drug events
These investments work toward meeting national goals to prevent drug-resistant infections as outlined in the
National Action Plan for Combating Antibiotic-Resistant Bacteria.